Cross-cultural adaptation and validation
of the RhinAsthma Patient Perspective (RAPP)
in the Polish population

Kupczyk, Maciej; Baiardini, Ilaria; Molinengo, Giorgia; Loera, Barbara; Szydłowska, Dorota; Kuna, Piotr; Canonica, Giorgio Walter; Braido, Fulvio

doi:10.5114/ada.2020.93387

Cited by 3 publications

(1 citation statement)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RhinAsthma Patient Perspective (RAPP) is a simple eight‐question questionnaire with good measurement properties and sensitivity to health changes. It provides a valid, reliable, and standardized HRQoL measurement in patients with asthma and comorbid allergic rhinitis in the clinical practice 72–80 . RAPP discriminates between patients with different disease severity levels.…”

Section: The Aria‐eaaci Approach Using the Mask‐air® App In Allergic ...mentioning

confidence: 99%

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

Bousquet

Shamji

Antó

et al. 2023

Allergy

Self Cite

View full text Add to dashboard Cite

Biomarkers for the diagnosis, treatment and follow‐up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient‐reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real‐life studies and allergen challenges. Using the MASK‐air app as a model, a daily electronic combined symptom‐medication score for allergic diseases (CSMS) or for asthma (e‐DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real‐life, it secondly proposed quality‐of‐life digital biomarkers including daily EQ‐5D visual analogue scales and the bi‐weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.

show abstract

Section: The Aria‐eaaci Approach Using the Mask‐air® App In Allergic ...mentioning

confidence: 99%

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

Bousquet

Shamji

Antó

et al. 2023

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Wise

Damask

Roland

et al. 2023

Int Forum Allergy Rhinol

113

View full text Add to dashboard Cite

Background In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document. Methods ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work. Results ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost. Conclusion The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.

show abstract

Rhinitis and Asthma Patient Perspective (RAPP): Clinical Utility and Predictive Value

Baiardini

Fasola

Grutta

et al. 2022

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Cross-cultural adaptation and validation of the RhinAsthma Patient Perspective (RAPP) in the Polish population

Cited by 3 publications

References 37 publications

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

Rhinitis and Asthma Patient Perspective (RAPP): Clinical Utility and Predictive Value

Contact Info

Product

Resources

About